Clinical Trial Results:
A phase 2 trial of EO2040, a miCrobiaL-derived peptide therApeUtic vaccine, in combination with nivolumab, for treatment of patients with circulating tumor DNA-dEfined minimal residual disease of colorectal cancer stage II, III, or IV after completion of curative therapy (the "CLAUDE" study).
Summary
|
|
EudraCT number |
2022-002679-12 |
Trial protocol |
DE ES |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Sep 2025
|
First version publication date |
13 Sep 2025
|
Other versions |
|
Summary report(s) |
EOCRC1-22_CLAUDE_CSR_Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.